Chiyoda-ku, Japan

Mika Fujinuma

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Mika Fujinuma

Introduction

Mika Fujinuma is a prominent inventor based in Chiyoda-ku, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that address various health issues. Her work is characterized by a focus on innovative solutions for complex medical conditions.

Latest Patents

Mika Fujinuma holds a patent for a pyridine derivative, which is represented by formula (I). This compound is a prodrug, a pharmaceutically acceptable salt, or a solvate of the pyridine derivative. It is particularly useful for the treatment or prophylaxis of diseases associated with URAT1, including gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis, and Lesch-Nyhan syndrome. She has 1 patent to her name, showcasing her innovative approach to pharmaceutical development.

Career Highlights

Mika is currently employed at Teijin Pharma Limited, where she continues to advance her research and development efforts. Her work at Teijin Pharma has positioned her as a key player in the pharmaceutical industry, contributing to the development of new therapeutic options.

Collaborations

Mika collaborates with notable colleagues, including Akinobu Maruyama and Hirofumi Kamada. These partnerships enhance her research capabilities and foster innovation within her projects.

Conclusion

Mika Fujinuma's contributions to the field of pharmaceuticals through her innovative patent on pyridine derivatives highlight her role as a leading inventor. Her work not only addresses critical health issues but also exemplifies the importance of collaboration in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…